PARIS, March 21, 2014 /PRNewswire/ --
Altran and Oxo Pharma have entered into a partnership formed for the purposes of addressing one of the key issues in the Pharmaceuticals industry: that of mastering and improving quality systems.
For Altran and Oxo Pharma, the objective is to provide a full-range of expertise aimed at reducing the level of error by simplifying the documentation system. This disruptive innovative approach changes the paradigm, making it possible to reconfigure systems, by placing the technical pharmaceuticals operator at the centre of the quality system, and to measure the efficiency of quality systems in a reliable way thanks to the rate of Overall Document Efficiency (ODE).
Quality systems in the spiral towards increased complexity
Quality pharmaceutical systems, whose purpose is to guarantee drug quality and compliance, are subject to constant change required by frequent regulatory updates.
As a result, these systems are becoming increasingly more complex and costly, and less efficient.
The overall cost of quality is one of the key expenditure areas for laboratories (teams in charge of quality can account for up to 40% of the total workforce of a pharmaceuticals production plant). In their efforts to simplify and optimise quality-systems efficiency, quality departments are required to carry out a vast amount of projects which very often produces disappointing results in terms of error reduction.
A joint solution for a new model
The new joint offer proposed by Altran and Oxo Pharma is targeting an improvement in Overall Document Efficiency (ODE) rates of between 15% (the most common level attained) and 85%, while simplifying the documentation system by 30%, which makes for a 50% reduction in the amount of errors.
As such, the offer allows for a reduction in total quality costs. Moreover, efficiency improvement is guaranteed thanks to a unique approach which covers the definition of the quality-system optimisation strategy through to the implementation and final-result achievement stages.
Follow us on Twitter #altranPR
SOURCE Altran and Oxo Pharma